Late-Breaking Science sessions to present transformative findings

Attendees listening to sessionLeading cardiovascular experts will unveil the latest breakthroughs in the industry from Nov. 12-15 in Anaheim, California. The must-see lineup of Late-Breaking Science sessions at AHA’s Scientific Sessions will include results and updates from key trials and registries. The learning continues when you connect with researchers involved in select Late-Breaking Science trials during our Meet the Trialists sessions. See the full list of Late-Breaking Science sessions below:

Late-Breaking Science

Sunday, Nov. 12
CABG and EP Peri-Procedural Dilemmas

  • TRiCS III — An International Multicenter Randomized Trial of Transfusion Triggers in Cardiac Surgery
  • DACAB — Efficacy and Safety of Dual Acetylsalicylic Acid Plus Ticagrelor or Ticagrelor Alone Antiplatelet Strategy After Coronary Artery Bypass Surgery at 12 Months: Randomized Multicentre Trial
  • PRESERVE – Sodium Bicarbonate and N-Acetylcysteine for the Prevention of Serious Adverse Outcomes Following Angiography
  • BRUISE CONTROL-2 — A Randomized Controlled Trial of Continued Versus Interrupted Novel Oral Anticoagulant at the Time of Device Surgery
  • ABRIDGE J — Clinical Benefit of Minimally-Interrupted Dabigatran Versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Monday, Nov. 13
Late Breaking Science in Prevention

  • REAL-CAD — Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease
  • REVEAL — Effects of Anacetrapib on the Incidence of New-onset Diabetes Mellitus and on Vascular Events in People With Diabetes
  • FOURIER — Evolocumab and Outcomes in Patients With Peripheral Artery Disease
  • FOURIER — Clinical Benefit of Evolocumab in Patients With a History of MI
  • CANTOS — Residual Inflammatory Risk and Residual Cholesterol Risk: Critical Analysis

Latest Insights into Hypertension Management

  • Chinese BP Trial — Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality
  • SPRINT — Blood Pressure Measurement in the Systolic Blood Pressure Intervention Trial (SPRINT)
  • GATEWAY — Effects of Bariatric Surgery in Obese Patients With Hypertension

Sweet Spot in Cardiometabolic Care

  • CANVAS — Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes
  • EXSCEL — Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
  • EMPA-REG OUTCOME — Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients With Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis
  • BiomarCaRE — Serum Metabolomic Profiles Predict Coronary Heart Disease in the General Population — the Biomarcare Consortium

Tuesday, Nov. 14
New Insights into the Risks, Benefits, and Costs of Antithrombotic Therapy

  • COMPASS — Costs Impact Rivaroxaban Plus Aspirin Versus Aspirin in the COMPASS Trial
  • RE-DUAL PCI — Subgroup Analysis From the RE-DUAL PCI Trial: Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
  • POISE-2 PCI Substudy — Aspirin in Patients With Previous Percutaneous Coronary Intervention (PCI) Undergoing Noncardiac Surgery
  • GEMINI-ACS-1 — P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes
  • PRAGUE-18 — One-Year Outcomes of Patients With Acute Myocardial Infarction Treated With Primary Angioplasty and Randomized to Prasugrel Versus Ticagrelor — The Prague-18 Trial

Evaluating Quality Improvement and Patient Centered Care Interventions

  • SWEDEHEART Registry Results 1995-2014 — Improved Outcomes in Patients With Non-ST-Elevation Myocardial Infarction During 20 Years Are Related to Implementation of Evidence-Based Treatments
  • STIC2IT — Results of the Study of a Tele-Pharmacy Intervention for Chronic Diseases to Improve Treatment Adherence (STIC2IT)
  • ACS QUIK — Effect of a Quality Improvement Toolkit on Acute Myocardial Infarction in India: The ACS QUIK Cluster Randomized, Stepped Wedge Trial
  • NZ STEP WEDGE — National Implementation of a Clinical Guidance Framework for the Emergency Department Assessment of Patients With Possible Acute Coronary Syndromes
  • DECIDE-LVAD — Effectiveness of a Shared Decision Making Intervention for Patients Offered a Destination Therapy Left Ventricular Assist Device for End-Stage Heart Failure: the DECIDE-LVAD Trial
  • ACCELERATOR-2 — Regional STEMI Systems of Care: Results of the Mission: Lifeline STEMI ACCELERATOR-2 Study

Wednesday, Nov. 15
Innovative Therapies and Novel Applications

  • REDUCE LAP-HF — Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure: Results From the REDUCE LAP-HF I Randomized Controlled Trial
  • TNT-POAF — Temporary Neurotoxin Treatment to Prevent Postoperative Atrial Fibrillation
  • PROPEL — Granulocyte Macrophage Colony-Stimulating Factor With and Without Supervised Exercise to Improve Walking Performance in Peripheral Artery Disease
  • ALLSTAR — 6-Month Results of ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: A Randomized, Placebo-Controlled, Double-Blind Study
  • [HOPE]-Duchenne — Cardiosphere-Derived Cells for the Treatment of Duchenne Cardiomyopathy: Results of the Halt cardiOmyopathy ProgrEssion [HOPE]-Duchenne Trial

Meet the Trialists

10:45 a.m.-Noon
Room 213C (Main Building)
CABG and EP Peri-procedural Dilemmas

9-10:15 a.m.
Room 207B (Main Building)
Late Breaking Science in Prevention

10:45 a.m.-Noon
Room 210D (Main Building)
Sweet Spot in Cardiometabolic Care

2-3:15 p.m.
Room 208AB (Main Building)
New Insights into the Risks, Benefits and Costs of Antithrombotic Therapy

5:30-6:45 p.m.
Room 210C (Main Building)
Evaluating Quality Improvement and Patient Centered Care Interventions